Abiopharma

🔍 Cowan Elvia (Executive)

Company: Vaxcyte, Inc. (PCVX)

Report Date: 2026-03-09

Detailed Transactions and Holdings:

• Sold 495 shares of Common Stock at $59.32 per share (Direct)
  Date: 2026-03-09 | Code: F | equity_swap_involved: 0 | shares_owned_after: 30,867.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 2,500 shares of Common Stock at $25.92 per share (Direct)
  Date: 2026-03-11 | Code: M | equity_swap_involved: 0 | shares_owned_after: 33,367.00 | transaction_form_type: 4
• Sold 2,500 shares of Common Stock at $58.5927 per share (Direct)
  Date: 2026-03-11 | Code: S | equity_swap_involved: 0 | shares_owned_after: 30,867.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 2,500 shares of Stock Option (right to buy) at $25.92 per share (Derivative)
  Date: 2026-03-11 | Code: M | Expires: 2032-08-08 | equity_swap_involved: 0 | shares_owned_after: 96,068.00 | transaction_form_type: 4 | Footnotes: F3

Footnotes:

• F1: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs. No other shares of common stock subject to the restrictions on transfer set forth in a Lock-Up Agreement dated January 29, 2026 were sold by the Reporting Person.
• F2: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2025.
• F3: 1/4 of the shares subject to the option vested on July 1, 2023, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.